Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the international MSLT-II trial, which looks at the possibility of less surgery for melanoma patients in the future.
Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the international MSLT-II trial, which looks at the possibility of less surgery for melanoma patients in the future.
Luke says the trial is investigating lymph nodes and how medical professionals are diagnosing tumors. He adds that while a lymph node may come up positive for melanoma, the test may only be showing one cancerous cell that could be taken out without as much surgery.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More